Marshall Wace
SYRE icon

Marshall Wace’s Spyre Therapeutics SYRE Stock Holding History

Marshall Wace’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.02M Buy
+139,259
New +$5.25M 0.01% 1135
2024
Q2 		– Sell
-161,921
Closed -$6.14M – 2946
2024
Q1 		$6.14M Buy
161,921
+141,669
+700% +$4.1M 0.01% 919
2023
Q4 		$436K Buy
+20,252
New +$279K ﹤0.01% 1762
2022
Q2 		– Sell
-6,167
Closed -$355K – 3831
2022
Q1 		$355K Buy
6,167
+4,502
+270% +$378K ﹤0.01% 2919
2021
Q4 		$197K Sell
1,665
-10,968
-87% -$1.73M ﹤0.01% 3160
2021
Q3 		$2.51M Sell
12,633
-13,423
-52% -$2.35M 0.01% 1387
2021
Q2 		$4.53M Sell
26,056
-21,594
-45% -$3.92M 0.02% 897
2021
Q1 		$9.44M Sell
47,650
-2,080
-4% -$399K 0.04% 483
2020
Q4 		$9.78M Buy
49,730
+33
+0.1% +$6.84K 0.05% 357
2020
Q3 		$8.81M Sell
49,697
-260
-0.5% -$48.1K 0.06% 339
2020
Q2 		$11.6M Buy
49,957
+16,391
+49% +$3.12M 0.08% 246
2020
Q1 		$3.91M Buy
33,566
+230
+0.7% +$39.1K 0.04% 448
2019
Q4 		$6.37M Buy
33,336
+1,312
+4% +$258K 0.04% 450
2019
Q3 		$6.16M Buy
32,024
+5,676
+22% +$1.11M 0.05% 439
2019
Q2 		$4.51M Buy
26,348
+11,312
+75% +$1.96M 0.04% 523
2019
Q1 		$3.03M Buy
+15,036
New +$3.13M 0.03% 626

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Marshall Wace's SYRE Position: Q1 2026 in Review

Marshall Wace opened a new position in Spyre Therapeutics (SYRE) in Q1 2026: 139,259 shares worth $7.02M. The stake represents 0.01% of the portfolio and ranks #1135 among its holdings. This is a return to the name: Marshall Wace previously reported a position in SYRE as recently as Q1 2024.

Marshall Wace first reported a position in SYRE in Q1 2019 and has held it in 16 quarters since. The position peaked at $11.6M in Q2 2020. 197 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

  • Marshall Wace held 139,259 shares of Spyre Therapeutics worth $7.02M as of Q1 2026.
  • Spyre Therapeutics was a new Marshall Wace position in Q1 2026.
  • Spyre Therapeutics made up 0.01% of Marshall Wace's portfolio in Q1 2026, its #1135 holding.
  • Marshall Wace first reported a position in Spyre Therapeutics in Q1 2019 and has held it in 16 quarters since.
  • Marshall Wace's Spyre Therapeutics position peaked at $11.6M in Q2 2020.
  • 197 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.